The SUMMIT trial evaluates Tirzepatide in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, a significant and growing market due to the increasing prevalence of obesity and heart failure. If successful, Tirzepatide could capture a substantial share of the heart failure treatment market, particularly as current therapies often have limited efficacy in this patient population. Competitive implications include potential differentiation from existing heart failure treatments and obesity medications, positioning Eli Lilly favorably against competitors. Diligence considerations should focus on the safety profile, long-term efficacy, and potential market access challenges.